loading page

T-cell Immunity Against COVID-19 and UK Variant in Infected and Vaccinated Individuals
  • +14
  • Stanley Jordan,
  • Bong-Ha Shin,
  • Terry-Ann Milfordgadsden,
  • Maggie Chu,
  • Anna Petrosyan,
  • Catherine Le,
  • Rachel Zabner,
  • Jillian Oft,
  • Isabel Pedraza,
  • Norkio Ammerman,
  • Susan Cheng,
  • Ashley Vo,
  • Jasmine Plummer,
  • Anders Berg,
  • Shili Ge,
  • Mieko Toyoda,
  • Ruan Zhang
Stanley Jordan
Cedars Sinai Med Ctr

Corresponding Author:[email protected]

Author Profile
Bong-Ha Shin
Cedars Sinai Med Ctr
Author Profile
Terry-Ann Milfordgadsden
Cedars Sinai Med Ctr
Author Profile
Maggie Chu
Cedars Sinai Med Ctr
Author Profile
Anna Petrosyan
Cedars Sinai Med Ctr
Author Profile
Catherine Le
Cedars Sinai Med Ctr
Author Profile
Rachel Zabner
Cedars Sinai Med Ctr
Author Profile
Jillian Oft
Cedars Sinai Med Ctr
Author Profile
Isabel Pedraza
Cedars Sinai Med Ctr
Author Profile
Norkio Ammerman
Cedars Sinai Med Ctr
Author Profile
Susan Cheng
Cedars Sinai Med Ctr
Author Profile
Ashley Vo
Cedars Sinai Med Ctr
Author Profile
Jasmine Plummer
Cedars Sinai Med Ctr
Author Profile
Anders Berg
Cedars Sinai Med Ctr
Author Profile
Shili Ge
Cedars Sinai Med Ctr
Author Profile
Mieko Toyoda
Cedars Sinai Med Ctr
Author Profile
Ruan Zhang
Cedars Sinai Med Ctr
Author Profile

Abstract

Understanding the composition of human immune responses to SARS-CoV-2 and vaccines is essential for predicting protection from infection and determining vaccine efficacy. Here, we explored T-cell immune responses to SARS-CoV-2 and the UK (B.1.1.7) variant of concern (VOC) in infected and vaccinated individuals. In infected patients, CD4+ T-cells demonstrated consistent, robust responses against Spike peptides, while CD8+ T-cells had heterogeneous responses to 5 SARS-CoV-2 proteins. We found 80% of infected and vaccinated individuals showed positive CD4+ T-cell immunity against SARS-CoV-2. Moreover, CD4+/CD8+ T-cell responses to SARS-CoV-2 and the United Kingdom (B.1.1.7) variant are robust and nearly identical in infected and vaccinated individuals. Thus, the UK variant did not interfere with T-cell recognition and elicited responses. These observations will be of critical importance in assessing human immune responses to emerging VOCs.